Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FTC supplements settlement

This article was originally published in The Tan Sheet

Executive Summary

Gero Vita International and six related defendants are required to pay monetary judgments of $605,000 after settling Federal Trade Commission charges related to deceptive marketing practices, FTC reports June 8. The defendants, including dietary supplement direct marketer Almon Glenn Braswell, claimed their products could cure or treat illnesses and conditions such as diabetes, Alzheimer's disease and obesity, the agency says. FTC originally filed the complaint in May 2003 (1"The Tan Sheet" June 2, 2003, p. 13). The defendants are barred from making future misleading product claims in addition to the fines. The $605,000 settlement resulted from the suspension of a $30 mil. judgment based on the defendants' inability to pay. However, the defendants will have to pay the total $30 mil. if they misrepresented their financial condition or Braswell does business with any other defendant, FTC says...

You may also be interested in...

Braswell Supplement Operations Charged With False Advertising By FTC

Dietary supplement direct marketer Almon Glenn Braswell and four of his corporations falsely represented New Life Nutrition magazine as an "independent publication and not paid advertising," according to an 1FTC complaint filed in Los Angeles federal court May 27

EU’s SCCS Finds Endocrine-Disrupting Evidence Inconclusive In UV Filter Reassessments

While endocrine-disrupting evidence was inconclusive, the Scientific Committee on Consumer Safety recommends more conservative limits on use of homosalate, octocrylene and benzophenone-3 in cosmetic products compared with current requirements under the European Cosmetics Product Regulation.

US FDA Urges COVID-19 Transmission Risk Mitigation In Cell And Gene Therapy Manufacturing

The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts